Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma 1

Interventions

pembrolizumab 4aflibercept 2Nivolumab 2vocimagene amiretrorepvec 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1gallium maltolate 1erdafitinib 1epacadostat 1entinostat 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1ciforadenant 1cemiplimab 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × gallium maltolate × Lymphoid × Clear all
NCT00050687 2011-01-28

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Titan Pharmaceuticals

Phase 1/2 Terminated
GenitourinaryLymphoidPlasma cell

Urinary Bladder Neoplasms, Lymphoma, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡